Guardant Health Shares Surge 258% Over Past Year on Cancer Test Demand
Precision oncology firm Guardant Health reports strong growth driven by rising adoption of its blood and tissue cancer tests. Guardant Health (NASDAQ:GH) closed at $159.79 on August 04, 2026, reflecting a 258.35% gain over the past 52 weeks. The company’s shares rose 2.32%